Strategic management paper for Boehriger Ingelheim Philippines

Date of Publication

2006

Document Type

Oral Comprehensive Exam

Degree Name

Master of Business Administration

College

Ramon V. Del Rosario College of Business

Department/Unit

Decision Sciences and Innovation

Defense Panel Chair

Louie A. Divinagracia

Defense Panel Member

Benjamin Espiritu
Tristan H. Macapanpan

Abstract/Summary

Boehringer Ingelheim Philippines is a wholly-owned subsidiary of Boehringer Ingelheim International GmBH, with headquarters in the city of Ingelheim am Rhein, Germany. Boehringer Ingelheim Philippines belongs to the Australasia section

Boehringer Ingelheim Phil, Inc. (BIPHI) is one of the leading pharmaceutical companies in the Philippines. It markets human and animal health products (prescription medicines, consumer health products and animal vaccines) that are known for their quality and efficacy. The human pharmaceuticals business accounts for 95 percent (70.2% Prescription Medicines and 24.8% CHC) of the company's total revenue while the animal health division accounts for only 5%. The product line of Boehringer Ingelheim, (Phil.) Inc. is composed of cardiovascular, respiratory and neurological medicines.

Boehringer Ingelheim, Phils. is divided into three divisions the Prescription Medicines Division, Consumer Health Care Division and the Animal Health Division. The Consumer Health Care Division markets OTC (over-the-counter) drugs such as Pharmaton, Dulcolax, Kiddi Pharmaton, and Bisolvon.

The Prescription Medicines Division (Ethical) presently markets drugs such as Mucosolvan, Spiriva, Micardis, Micardis Plus, Sifrol, Mobic, Primavent, Persantin, Berodual, Combivent UDV, Aggrenox and Buscopan.

The Animal Health Division markets animal vaccines such as Ingelvac, Enterisol, Reprocycle, Volvac and Bar Somnus.

Abstract Format

html

Language

English

Format

Electronic

Accession Number

CDOCE00951

Shelf Location

Archives, The Learning Commons, 12F Henry Sy Sr. Hall

Physical Description

1 computer optical disc ; 4 3/4 in.

Keywords

Pharmaceutical industry--Philippines; Veterinary drug industry--Philippines; Boehriger Ingelheim Philippines

This document is currently not available here.

Share

COinS